Stock Market Reviews

Read and share opinions on ELVN (Enliven Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

Latest News

• /C O R R E C T I O N -- Enliven Therapeutics, Inc./
  Nov 13, 2025
• Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting
  Nov 3, 2025
• Assessing Enliven Therapeutics (ELVN) Valuation as Shares Show Signs of Short-Term Momentum
  Oct 24, 2025
• Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know
  Sep 12, 2025
• Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
  Sep 9, 2025
• How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%
  Aug 27, 2025
• Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
  Aug 25, 2025
• Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
  Aug 13, 2025
• Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
  Jul 18, 2025
• Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
  Jun 17, 2025
• Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
  Jun 16, 2025
• Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
  Jun 13, 2025
• Enliven's Chronic Myeloid Leukemia Candidate Achieves MMR Rate in Phase 1 Trial
  Jun 13, 2025
• Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
  Jun 13, 2025
• Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
  Jun 13, 2025
• Enliven Therapeutics to Present at Upcoming Investor Conferences
  May 22, 2025
• Enliven price target lowered to $27 from $36 at JonesResearch
  May 17, 2025
• Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
  May 14, 2025
• Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress
  May 14, 2025